Jendle J, et al. - Researchers examined treatment satisfaction with semaglutide vs placebo/active comparators in the SUSTAIN clinical trial program. In SUSTAIN 2–5 and 7, the Diabetes Treatment Satisfaction Questionnaire was utilized to assess patient-perceived treatment satisfaction, hyperglycemia, and hypoglycemia. Findings suggested an association of semaglutide with significantly greater (SUSTAIN 2–5) or comparable (SUSTAIN 7) improvements in overall treatment satisfaction vs comparators/placebo. Improvements in overall therapy satisfaction were generally higher in patients achieving vs not achieving treatment targets. No differences were noted between treatments for perceived hypoglycemia.